The antitumor activity of Diosgenin in vivo and in vitro.
- Author:
Li-juan WANG
1
;
Yan WANG
;
Sheng-wu CHEN
;
Ji-sheng MA
;
Qin FU
;
Ben-xiang WANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antineoplastic Agents, Phytogenic; therapeutic use; Carcinoma, Ehrlich Tumor; drug therapy; Dioscorea; chemistry; Diosgenin; isolation & purification; therapeutic use; Female; Humans; Inhibitory Concentration 50; Male; Mice; Neoplasm Transplantation; Phytotherapy; Plants, Medicinal; chemistry; Sarcoma 180; drug therapy; Tumor Cells, Cultured; drug effects
- From: China Journal of Chinese Materia Medica 2002;27(10):777-779
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the antitumor activity of Diosgenin in vivo and in vitro.
METHODS-180, HepA, U14 and EAC transplant mice were given Diosgenin ig or i.p. everyday for 10 days, from the next day when they were inoculated in axilla. Tumor growth inhibit rates were calculated. Four kinds of cells, MCF, L929, A375-S2 and HeLa, were incubated respectively with Diosgenin in vitro. Tumor growth inhibit rates were also calculated.
RESULTIn vivo, both ig and i.p., Diosgenin inhibited S-180, HepA, U 14 mice transplant tumor, the inhibit rates being 30%-50%, but it did not inhibit the EAC mice transplant tumor. In vitro, Diosgenin inhibited L929, HeLa, MCF cell growth, and IC50 were 1.2, 18.2, 19.8 micrograms.mL-1 respectively, but it did not significantly affect A375-S2 cells.
CONCLUSIONDiosgenin has an obvious antitumor activity on S-180, HepA, U14 transplant mice in vivo and L929, HeLa, MCF cells in vitro.
